Albert David Ltd
Incorporated in 1938, Albert David
Ltd is in the business of manufacturing pharmaceutical products[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Large Volume Parenterals ₹ Lakhs ・Standalone data |
|
||||||||||
| Revenue from Syrups/Liquids ₹ Lakhs ・Standalone data |
|||||||||||
| Total Number of Permanent Employees Number ・Standalone data |
|||||||||||
| Number of Stockists Number ・Standalone data |
|||||||||||
| Contribution of Top Product (Placentrex) % ・Standalone data |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||||||
Documents
Announcements
- Closure of Trading Window 23 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
13 Mar - Re-lodgement of transfer of 300 Nos. of Physical Equity Shares by Mr. Bharat Kumar N Jain as per SEBI Circular No. SEBI/HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated 30th January, …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
11 Mar - Newspaper Publication regarding special window for re-lodgement of transfer requests of physical shares
-
Announcement under Regulation 30 (LODR)-Change in Management
10 Mar - International Business Leader Thakkar Rushabh Kishorbhai resigns; notice period ends 27 March 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Feb - Newspaper Publication of Extract of Unaudited Financial Result for the third quarter and nine months ended 31st December, 2025
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ADL is a part of the Kolkata-based Kothari Group. It is a prominent drug house, which is in the field of manufacturing Pharmaceutical Formulations, Infusion Solutions, Herbal Dosage Forms, Bulk Drugs, etc. Company is in strategic liaison with academic institutes like the Indian Institute of Chemical Biology (CSIR) & Department of Biotechnology, Calcutta University for outsourcing research.